Bashar A Zeidan1, Paul A Townsend2, Spiros D Garbis1, Ellen Copson1, Ramsey I Cutress3. 1. Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton University Hospitals NHS Foundation Trust, Southampton, SO16 6YD, UK. 2. Faculty Institute for Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, St Mary's Hospital, Oxford Road, Manchester, M13 9WL, UK. 3. Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton University Hospitals NHS Foundation Trust, Southampton, SO16 6YD, UK. Electronic address: r.i.cutress@soton.ac.uk.
Abstract
BACKGROUND: Breast cancer is a heterogeneous disease. Yet, many molecular players and mechanisms behind the complexity of its clinical behaviour remain unknown, and advances in biomedical research are expected to unravel novel molecular discoveries in breast and other cancers. Clinical proteomics is currently experiencing rapid advances in technology that promise new means to improve breast cancer early diagnosis, stratification, and treatment response. METHODS: We reviewed recent literature adopting clinical proteomics in breast cancer research. FINDINGS: This review highlights the principles, advantages, limitations, discoveries and future prospects of recent clinical proteomics discovery efforts in breast cancer research. CONCLUSION: Numerous proteomic studies of breast cancer have been accomplished aiming to aid the development of personalised therapies, increase understanding of post treatment relapse, and help improve prediction of patient prognosis. This has led to the possible identification of profiles refining breast cancer subtypes and the discovery of novel biomarkers pointing towards diagnostic and prognostic potential.
BACKGROUND:Breast cancer is a heterogeneous disease. Yet, many molecular players and mechanisms behind the complexity of its clinical behaviour remain unknown, and advances in biomedical research are expected to unravel novel molecular discoveries in breast and other cancers. Clinical proteomics is currently experiencing rapid advances in technology that promise new means to improve breast cancer early diagnosis, stratification, and treatment response. METHODS: We reviewed recent literature adopting clinical proteomics in breast cancer research. FINDINGS: This review highlights the principles, advantages, limitations, discoveries and future prospects of recent clinical proteomics discovery efforts in breast cancer research. CONCLUSION: Numerous proteomic studies of breast cancer have been accomplished aiming to aid the development of personalised therapies, increase understanding of post treatment relapse, and help improve prediction of patient prognosis. This has led to the possible identification of profiles refining breast cancer subtypes and the discovery of novel biomarkers pointing towards diagnostic and prognostic potential.
Authors: A I Autenshlyus; A V Bernado; A A Studenikina; A V Proskura; K I Davletova; I P Zhurakovskiy; S A Arkhipov; N A Varaksin; S V Sidorov; V V Lyakhovich Journal: Dokl Biochem Biophys Date: 2020-04-27 Impact factor: 0.788
Authors: Eleni Zografos; Stavros C Proikakis; Athanasios K Anagnostopoulos; Anna-Maria Korakiti; Flora Zagouri; Maria Gazouli; George T Tsangaris Journal: Cancer Genomics Proteomics Date: 2022 Mar-Apr Impact factor: 4.069
Authors: S Zhao; J Feng; C Li; H Gao; P Lv; J Li; Q Liu; Y He; H Wang; L Gong; D Li; Y Zhang Journal: J Endocrinol Invest Date: 2018-04-24 Impact factor: 4.256
Authors: Bashar Zeidan; Antigoni Manousopoulou; Diana J Garay-Baquero; Cory H White; Samantha E T Larkin; Kathleen N Potter; Theodoros I Roumeliotis; Evangelia K Papachristou; Ellen Copson; Ramsey I Cutress; Stephen A Beers; Diana Eccles; Paul A Townsend; Spiros D Garbis Journal: Breast Cancer Res Date: 2018-03-22 Impact factor: 6.466
Authors: Axel Ducret; Ian James; Sabine Wilson; Martina Feilke; Andreas Tebbe; Nikolaj Dybowski; Sarah Elschenbroich; Martin Klammer; Adele Blackler; Wei-Li Liao; Yuan Tian; Thomas Friess; Birgit Bossenmaier; Gabriele Dietmann; Christoph Schaab; Todd Hembrough; Maurizio Ceppi Journal: PLoS One Date: 2019-03-21 Impact factor: 3.240